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Fibrosis of oesophagus, lungs, heart, and kidney in the course of systemic sclerosis (SSc) may lead to dysfunction of the above
organs or even patients death. Recent studies point out the role of angiogenesis and ﬁbrosis disturbances in the pathogenesis of SSc.
HeartﬁbrosisisoneofthemostimportantprognosticfactorsinSScpatients.So,theaimofourstudywastoexaminecardiovascular
dysfunctioninSScpatientsanditscorrelationwithserumlevelsofvascularendothelialgrowthfactor(VEGF),endostatin,andtissue
inhibitor of metalloproteinase 2 (TIMP2). The study group comprised 34 patients (19 with limited scleroderma (lSSc) and 15 with
diﬀuse scleroderma (dSSc)). The control group consisted of 20 healthy persons, age and sex matched. Internal organ involvement
was assessed on the basis of specialist procedures. Serum VEGF, endostatin, and TIMP2 levels were evaluated by ELISA. We found
cardiovascular changes in 15 patients with SSc (8 with lSSc and 7 with dSSc). The observed symptoms were of diﬀerent characters
and also coexisted with each other. Higher endostatin serum levels in all systemic sclerosis patients in comparison to the control
groupweredemonstrated(P< .05).AlsohigherserumlevelsofendostatinandTIMP2wereobservedinpatientswithcardiovascular
changes in comparison to the patients without such changes (P< .05). The obtained results support the notion that angiogenesis
and ﬁbrosis disturbances may play an important role in SSc. Evaluation of endostatin and TIMP2 serum levels seems to be one of
the noninvasive, helpful examinations of heart involvement in the course of systemic sclerosis.
INTRODUCTION
Systemic sclerosis (sclerodermia sistemica, scleroder-
ma—SSc) is a chronic, multifactorial disease which was
ﬁrst described by Goetz [1]. Pathogenesis of this disease
still remains not fully elucidated. The disease can run ei-
ther a chronic or violent course which depends on the de-
gree of internal organs dysfunction. This dysfunction can
evenleadtopatientsdeath[2,3].Literaturedatapointout
that small and large blood vessel disturbances and ﬁbrosis
development play a key role in connective tissue changes
of immunological character [4].
In healthy tissues angiogenesis does not take place be-
cause of equilibrium levels of proangiogenic and antian-
giogenic factors. The following factors are known to trig-
ger angiogenesis, that is, vascular endothelial growth fac-
tor (VEGF), basic ﬁbroblast growth factor (bFGF), and
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interleukin-18 (IL-18) [5, 6, 7], whereas endostatin, TGF-
β,T N F - α, interleukin-10 (IL-10), as well as tissue in-
hibitor of metalloproteinases 1, 2, 3 (TIMP1, 2, 3) have
antiangiogenic activity [5]. Literature data reporting in-
hibitoryeﬀectsonangiogenesisexertedbymonocytesand
lymphocytes obtained from systemic sclerosis patients
couldfurthersupport theimportance ofangiogenesis dis-
turbances in the development of systemic sclerosis [8, 9].
Impairment of collagen I, collagen III, collagen V, col-
lagen VI, collagen VII synthesis in SSc leads to skin and
internal organ ﬁbrosis. Recent research data underline the
important role of proteases in extracellular matrix degra-
dation, including collagen, in the course of this disease
[10]. It is worth pointing out that matrix metallopro-
teinases (MMPs) belong to the group of proteases. Those
enzymes activity depends on zinc and calcium ions pres-
ence. MMPs are synthesized and released by ﬁbroblasts,
monocytes, granulocytes, T lymphocytes, dendritic cells,
macrophages, endothelial cells, microglia, epithelial cells,
myocytes, and astrocytes [11]. Tissue inhibitors of pro-
teinases (TIMPs) are suggested to play a more important
role in ﬁbrosis development than proteolytic enzymes.
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their proteolytic enzymes [12]. They exert an inhibitory
eﬀect on metalloproteinases activation and further also
on active forms of those enzymes [13]. Up till now, four
TIMPs have been described, out of which the role of three
has been fairly well elucidated, that is, TIMP1, 2, and 3
[14]. Homeostasis disturbances between MMPs and their
tissue inhibitors could be responsible for changes in ex-
tracellular matrix composition.
Heart involvement could be one of the most impor-
tant prognostic factors in the course of SSc [15]. Heine,
already in 1926, was the ﬁrst scientist to describe heart
disturbances in SSc [16]. It should be noted that cardio-
vascular changes could develop at any stage of the dis-
ease. However, clinical symptoms have not been charac-
teristic and manifest fairly late thus leading to late diag-
nosis and subsequent delay in proper treatment [17]. The
most common complaints reported by the patients with
heart involvement are palpitations, dyspnoea, fatigability,
and vague pain in the chest [18]. Myocardial ﬁbrosis may
lead to conduction disturbances and arrhythmia. Exuda-
tivepericarditishasbeenalsoreportedinthecourseofSSc
[19].
Myocardial ischaemia, resulting from coronary vessels
spasms, observed in SSc patients may resemble peripheral
Raynaud’s phenomenon [15]. In SSc patients, more often
than in the general population, morphological changes
of heart structures, specially of the mitral valve, are ob-
served [20]. Employment of echocardiography, spiroer-
gometry, perfusion scintigraphy of the myocardium, 24-
hour heart rhythm monitoring allow to detect clinically
“silent” changes [21, 22].
The aim of our study was to evaluate cardiovascular
changes in SSc patients and assess serum levels of VEGF,
endostatin, and TIMP2 in those patients.
MATERIALS AND METHODS
The study involved 34 SSc patients, 26 women and 8
men, of age range 16–69 years. In our group 15 patients
presented diﬀuse form (dSSc) (mean 45.4 ± 12.5y e a r s )
and 19 limited SSc (lSSc) (mean age 50.7±13.3y e a r s ) .A l l
the patients were diagnosed according to American Col-
lege of Reumatology (ACR) criteria [23].
Because of the illness course, all dSSc subjects were
on disease-modifying drugs, that is, cyclophosphamide
(50mg daily), prednisone (15–20mg daily) or combina-
tion of both agents in the same doses as in monothera-
pies (treatment duration: 3–168 months, mean: 27 ± 48
months). The remaining 19 patients never received the
above medication. Patients from both subgroups were
treated with nifedipine (10mg daily) and vitamin E
(400mg daily) for at least 5 months.
The degree of skin sclerosis was assessed using the
total skin score (TSS) according to Kahaleh et al (0–66
points) [24].
Functional evaluation of four internal organs and sys-
tems,thatis,oesophagus,cardiovascularsystem,jointand
bone system, and lungs was performed by oesophagal
scintigraphy, 24-hour ECG monitoring (3-channel Ox-
ford Medilog Excel-2), Doppler echocardiography (H-
P 2500 apparatus), X-ray examination of feet and hand
bone, X-ray chest examination, and DLCO (diﬀusing ca-
pacity of the lung for carbon monoxide) (expressed in
percentages of the predicted value; pulmonary changes
were diagnosed when DLCO was below 80% of the pre-
dicted value).
Blood was collected in the morning into the pyrogen-
free tubes and stored in −20◦C until further evaluated.
VEGF levels were measured in 33 patients (19 with lSSc
and 14 with dSSc) and endostatin in 30 patients (16 with
lSSc and 14 with dSSc). The control group consisted of
20 healthy persons (19 female, 1 male; aged 25–64 years,
mean age: 46.3 ± 13.2 years). TIMP2 serum levels were
measured in 21 patients (9 with lSSc and 12 with dSSc)
and 10 healthy persons (8 women and 2 men; aged 20–64
years, mean age: 47.2 ±12 years).
VEGF, endostatin, and TIMP2 serum levels were
evaluated by enzyme immunoassay technique (ELISA)
(Quantikine R&D Systems Inc, Minneapolis Minn;
Oncogene Research Products, Boston, Mass; Amersham,
Pharmacia Biotech, England, UK). Detection sensitiv-
ity of the examined cytokines was 9.0pg/mLforVEGF ,
1.953ng/mL for endostatin, and 0.011ng/mL for TIMP2.
This TIMP-2 assay detects approximately 50% of re-
combinant human TIMP-2 when complexed with re-
combinant human active MMP-9 in a 1:1 molar ratio.
rhMMP-2 cross-reacts 0.002% at concentrations greater
than 2.5ng/mL.
Antinuclear antibody titres were examined by indirect
immunoﬂuorescence test on HEp-2 cells.
All patients and individuals from the control group
gavetheirinformedconsenttoparticipateinourstudyac-
cording to the Bioethic Committee of Medical University
of Lodz requirements.
STATISTICAL ANALYSIS
The obtained results were expressed as mean, maxi-
mum, minimum, and median values together with stan-
darddeviation(SD).Numericalvariablesdistributionwas
assessed by Shapiro-Wilk test. Mann-Whitney, Cochran-
Cox,andtwoindependentsampletestswereemployedfor
comparison of mean or median values. Correlations be-
tweenserumlevelsofVEGF,endostatinandheartinvolve-
ment were evaluated by Fisher precisely test with correla-
tion coeﬃcient Q. A P value less than .05 was considered
to be statistically signiﬁcant.
RESULTS
Clinical characteristics of the patients are presented in
Table 1.
We revealed disturbances in diﬀerent internal organs,
thatis,oesophagusin26/34SScpatients(15withlSScand146 Bo˙ zena Dziankowska-Bartkowiak et al 2005:3 (2005)
Table 1. Clinical characteristics of the examined groups. (A) denotes the control group for the examined angiogenesis factors; (B) de-
notes the control group for the examined TIMP2; SD denotes the standard deviation; n is the number of patients; TSS is the total skin
score; ANA denotes antinuclear antibodies. ∗ denotes statistically signiﬁcant diﬀe r e n c e si nc o m p a r i s o nb e t w e e nl i m i t e da n dd i ﬀuse
systemic sclerosis (P<. 05). ∗∗ denotes statistically signiﬁcant diﬀerences in comparison to the control group (P<. 05). Oesopha-
gal changes included oesophagal scintigraphy disturbances: swallowed passage in the lower and/or central part of the oesophagus.
Cardiovascular abnormalities included tendency to tachyarhythmias, lower potentials of diﬀerent parameters describing variability of
cardiac rhythm or conduction system abnormalities, ventricular arrhythmia, silent ischaemic episodes, diastolic left ventricular dis-
turbances, and valvular lesions. Osteoarticular changes included changes in osteoarticular system: juxta-articular demineralisation,
jointspacenarrowingindigits.InterstitiallungdiseaseincludedDLCO< 80%ofpredictedvaluewithorwithoutX-raychestchanges:




Systemic Limited systemic Diﬀuse systemic Control group
sclerosis (SSc) sclerosis (lSSc) sclerosis (dSSc) (A) n = 20
n = 34 n = 19 n = 15 (B) n = 10
Age (y)
(A) 25–64
Range 16–70 27–70 16–64 (46)
(mean) (48) (50) (45) (B) 20–64
(47)
Sex (F/M) — 26/8 18/1 8/7
(A) 19/1
(B) 8/2




Interstitial lung disease 20/34 10/19 10/15
Osteoarticular changes 27/34 15/19 12/15
ANA 34/34 19/19 15/15
Mean ± SD 28.1 ±13.81 7 .8∗ ±5.14 1 .3∗ ±9.0
TSS Median 25.01 7 .04 4 .0
Range 12.0–53.01 2 .0–30.02 6 .0–53.0
Mean ± SD 194.0 ±196.8 219.5 ±228.4 159.6 ±144.6 271.2 ±201.0
VEGF Median 138.2 138.2 134.3 286.4
(pg/mL) Range 0.0–836.40 .0–836.40 .0–455.62 3 .7–708.5
n = 33 n = 19 n = 14 n = 20
Mean ± SD 113.6 ±60.7∗∗ 101.9 ±53.1 127.1 ±67.8∗∗ 73.6 ±25.9
Endostatin Median 107.2 101.4 124.27 7 .8
(ng/mL) Range 13.6–261.21 3 .6–209.61 8 .0–261.21 8 .0–110.4
n = 30 n = 16 n = 14 n = 20
Mean ± SD 80.0 ±31.57 9 .8 ±32.58 0 .2 ±32.29 1 .6 ±20.0
TIMP2 Median 65.06 1 .06 5 .19 0 .2
(ng/mL) Range 38.6–131.95 2 .6–128.93 8 .6–131.96 1 .9–135.9
n = 21 n = 9 n = 12 n = 10
11 with dSSc); lungs in 20/34 SSc patients (10 with lSSc
and10withdSSc);heartin15/34SScpatients(8withlSSc
and 7 with dSSc); osteoarticular changes in 27/34 SSc pa-
tients (15 with lSSc and 12 with dSSc).
Cardiovascular changes were observed in 15 SSc pa-
tients (8 with lSSc and 7 with dSSc). They were of dif-
ferent character and developed as single events or coex-
isted with each other. Twenty-four-hour ECG monitoring
showed a tendency to tachycardia. Mean heart rate in SSc
patients was 81 ± 11 in comparison to 71 ± 9o b s e r v e di n
the control group. Conduction disturbances were found
in 3 patients, 6 presented heart rhythm disturbances, and
other 6 presented episodes of ischaemia. Statistically sig-
niﬁcantly lower values of 24-hour heart rhythm moni-
toring were observed in SSc patients in comparison to
the control group. One patient presented late ventricu-
lar potentials. QT intervals were within normal limits.
Cardiographic examination did not reveal any impair-
ment of systolic function of the left ventricle in any of the
examined patients; however 6 patients presented impair-
ment of diastolic function of this ventricle. Eight patients
presented organic changes such as ﬁbrosis of the mitral
valve leaﬂets and/or aortic cusps; however only in two pa-
tients the changes were of hemodynamic importance.
It was demonstrated that mean levels of VEGF
were lower than those in the control group (194.0 ±
196.8pg/mL and 271.2 ±201.0pg/mL,respectivelyatP>
.05); endostatin were higher than those in the control
group (113.6±60.7ng/mLand73.6±25.9ng/mL,respec-
tively at P<. 05); and TIMP2 were not diﬀerent from the
control group (80.0 ±31.5ng/mLand91.6 ±20.0ng/mL,
respectively at P>. 05) (Table 1). Using Fisher test, we
did not ﬁnd any statistically signiﬁcant correlation be-
tween serum levels of the examined parameters and car-
diovascular changes (detailed data not presented). How-
ever, comparison of mean serum levels of VEGF, endo-
statin, and TIMP2 in patients with heart involvement
showed higher levels of endostatin than in the control2005:3 (2005) Heart Involvement and Serum Levels of Endostatin and TIMP2 in SSc 147
Table 2. Correlations between vascular endothelial growth factor (VEGF), endostatin, and tissue inhibitor of metalloproteinases 2
(TIMP2) serum levels and heart involvement in the diﬀerent groups examined (Fisher precisely test, coeﬃcient Q); n is the number








Parameter selected patients P
sSSc (n = 14)
VEGF (pg/mL) −0.067 0.091 −0.280 −0.636 P = .245
Endostatin (ng/mL) 0.766 0.800 0.280 0.636 P = .245
TIMP2 (ng/mL) 0.474 1.000 0.675 0.000 P = .441
Table 3. Comparison of VEGF, endostatin, and TIMP2 serum levels in systemic sclerosis patients with or without heart involvement.
(a1), (a2), and (a3) denote patients with heart involvement; (b1), (b2), and (b3) denote patients without heart involvement; SD is the




Systemic sclerosis (SSc) Limited systemic Diﬀuse systemic
sclerosis (lSSc) sclerosis (dSSc) P<. 05
+(a1) −(b1) +(a2) −(b2) +(a3) −(b3)
VEGF
pg/mL
Mean ± SD 241.1 ±257.9 154.8 ±120.7 320.7 ±316.5 145.8 ±98.0 150.2 ±114.8 168.9 ±157.7
Median 114.8 143.5 267.5 138.2 114.8 153.7 NS
Range 0.0–836.40 .0–455.6 0.0–836.40 .0–236.6 0.0–404.90 .0–455.6
n = 15 n = 18 n = 11 n = 11 n = 7 n = 7
Mean ± SD 140.9 ±59.38 6 .3 ±50.2 136.3 ±46.56 7 .4 ±34.2 146.2 ±74.9 108.0 ±59.1
Endostatin Median 123.68 4 .4 118.07 7 .8 124.8 114.8 (a1), (b1)
(ng/mL) Range 46.4–261.21 3 .0–194.4 82.0–209.61 3 .6–103.6 46.4–261.21 8 .0–194.4 (a2), (b2)
n = 15 n = 15 n = 8 n = 8 n = 7 n = 7
TIMP2
(ng/mL)
Mean ± SD 87.6 ±30.96 9 .9 ±31.1 92.0 ±33.85 5 .3 ±4.2 83.1 ±30.37 7 .2 ±36.7
(a2), (b2)
Median 73.56 0 .2 91.75 3 .2 70.96 4 .7
Range 54.6–128.93 8 .6–131.9 54.6–128.95 2 .6–60.2 54.6–124.43 8 .6–131.9
n = 12 n = 9 n = 3 n = 3 n = 6 n = 6
group (P<. 05); also such a tendency, however still sta-
tistically insigniﬁcant, was observed in the selected 14 SSc
patients (sSSc), in whom all 3 substances were assessed
(Table 2). It was also demonstrated that mean serum lev-
elsofendostatinandTIMP2werestatisticallysigniﬁcantly
higher in patients with heart changes than in the group of
patients without such changes (P< .05) (Table 3).
Antinuclear antibodies (ANA) were found in 34 pa-
tients. In 19 patients with lSSc the following ANA were
observed: anti-topoisomerase I (10 patients), U3RNP an-
tibodies (1 patient), U1RNP antibodies (2 patients), anti-
RNA polimerase I antibodies (1 patient), and antinu-
clear antibodies of unidentiﬁable speciﬁcity (5 patients).
IndSScpatientsthefollowingantinuclearantibodieswere
identiﬁed: anti-Scl 70 antibodies (10 patients, in two pa-
tients coexisted with anticentromere antibodies, ACA,
and in one patient coexisted with Ku antibodies) and
U3RNP (5 patients). No ACA antibodies were demon-
strated in any of the examined patients.
DISCUSSION
Coronary vessel changes and ﬁbrosis of the my-
ocardium are features of heart involvement in the course
of systemic sclerosis. Kucharz pointed out that heart
involvement is often symptomless [19]. Myocardial ﬁbro-
sis usually develops in subendocardial layer and does not
depend on blood supply, as in atherosclerosis. Kucharz
also revealed that ECG changes were observed in about
50% of systemic sclerosis patients [19]. Thickening of the
left ventricular wall, asymmetrical hypertrophy of inter-
ventricular septum, cardiomegaly, and exudative changes
in the pericardial sac have been described. Rodnan et al
was the ﬁrst group who demonstrated that apart from
vessel spasms, inﬂammatory changes and ﬁbrosis of coro-
nary vessel walls were important factors in myocardial is-
chaemia development [25].
Endostatin is found in blood, urine, and basement
membranes of many organs but its activity has not been
fullyelucidated[26].However,itisknownthatendostatin
speciﬁcally inhibits endothelial cell proliferation and mi-
gration stimulated by VEGF [27]. Endostatin also vastly
reduces inﬂow of endothelial cells to newly developed
basal membrane of the blood vessels [28]. In vitro, in-
cubation of endostatin with endothelial cells leads to cell
apoptosis [29].
Increased levels of endostatin were found in systemic
sclerosispatientsincomparisontothecontrolgroup[30].
Our results demonstrated signiﬁcantly increased serum
endostatin levels in scleroderma patients when compared148 Bo˙ zena Dziankowska-Bartkowiak et al 2005:3 (2005)
with the control group, too. Collagen type XVIII can be
found in the basement membrane of skin blood vessels
and internal organs involved in systemic sclerosis [31].
Other authors demonstrated increased endostatin serum
levels only in a small group of patients; however they did
not ﬁnd any correlation with clinical parameters [32]. In
SSc patients, especially with cardiovascular disturbances,
TIMP2 and endostatin action could be dependent on tis-
sue microenvironment. TIMP2 and endostatin may act
synergistically exerting their antiangiogenic action via not
yet fully elucidated pathways in SSc course. This action
could be also triggered by the treatment methods em-
ployed and could further result from systemic response of
the organism. However, despite not fully elucidated endo-
statin action, it could be assumed that this factor inhibits
activation of proenzymatic metalloproteinase 2 form and
catalytic actions of membrane metalloproteinases type 1
and type 2 [28]. Thus, endostatin exerts a considerable ef-
fect on accumulation of extracellular matrix components
and ﬁbrosis development in the internal organs. Our re-
sults point out statistically signiﬁcantly increased endo-
statin levels in scleroderma patients presenting cardiovas-
cular disturbances in comparison to the patients without
such abnormalities. Probably increased levels of this fac-
tor may also lead to inhibitory eﬀect of angiogenesis in
anoxied heart tissue.
Tissue inhibitor of metalloproteinase 2 is a protein of
21-kd molecular weight, released in a soluble form. This
protein exerts an inhibitory eﬀect on all active metallo-
proteinasesformsandcompeteswiththemasregardsreg-
ulation of the extracellular matrix amount [33]. Yazawa et
al demonstrated statistically signiﬁcantly increased serum
levels of both TIMP1 and TIMP2 in SSc patients than in
the control group [34].
The current study results did not reveal statistically
signiﬁcant diﬀerences as for TIMP2 serum levels between
SSc patients and the control group. However, our results
demonstrated statistically signiﬁcant diﬀerences of this
protein level in the serum of lSSc patients with/or with-
out heart involvement. So, this observation could further
support the importance of TIMP2 in the development of
cardiovascular changes. Excessive accumulation of colla-
gen type I could lead to heart muscle ﬁbrosis and restric-
tions in the systo-diastolic function of the heart ventri-
cles [35]. It can be further assumed that increased levels
of TIMP2 may lead to angiogenesis inhibition, thus in-
tensifying already triggered dysfunction of microcircula-
tion [36]. Imbalance of heart extracellular matrix com-
ponents and decreased number of capillaries could also
leadtooxygendiﬀusionrestrictionsandmyocytehypoxia.
Structural changes of heart walls probably result from im-
balance between production and destruction of extracel-
lular matrix components, proliferation and migration of
cells and their apoptosis and necrosis. Heart ﬁbroblasts
take part in the above processes via production of growth
factors and cytokines, which exert auto and paracrine ac-
tion. Those cells also interfere with proteinases quantity
and extracellular matrix composition. Thus, it seems rea-
sonable to conclude that the currently observed correla-
tion between TIMP2 levels and heart dysfunction may
be much more important in disturbances of extracellular
matrix degradation than ECM excessive accumulation.
The obtained results seem to conﬁrm an important
role of angiogenic and ﬁbrotic factors in the course of sys-
temic sclerosis, including development of cardiovascular
disturbances. They also suggest that evaluation of endo-
statin and TIMP2 serum levels in SSc patients could be
helpful in the assessment of the cardiovascular system.
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